No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 142 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Coming Full Circle on Cancer and Extrachromosomal DNA May 10, 2023 Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease... June 16, 2025 Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... September 16, 2024 EMA Recommends Extension of Therapeutic Indications for Osimertinib April 26, 2021 Load more HOT NEWS Should People Over Age 75 Be Screened for Colorectal Cancer? Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... Let’s talk about HPV: 6 common questions answered
